Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Candel Therapeutics, Inc. Market Cap
From what 1 stock analysts predict, the share price for Candel Therapeutics, Inc. (CADL) might increase by 114.01% in the next year. This is based on a 12-month average estimation for CADL. Price targets go from $11 to $11. The majority of stock analysts believe CADL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Candel Therapeutics, Inc. has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Candel Therapeutics, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CADL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Vernon Bernardino HC Wainwright & Co. | Buy | $11 | Reiterates | Nov 18, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $11 | Reiterates | Nov 13, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $11 | Reiterates | May 22, 2023 |
| Evan David Seigerman BMO Capital | Outperform | $3 | Maintains | May 15, 2023 |
| Judah Frommer Credit Suisse | Outperform | $7 | Maintains | Mar 31, 2023 |
| Judah Frommer Credit Suisse | Outperform | $8 | Maintains | Dec 7, 2022 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $11 | Initiates | Dec 2, 2022 |
BMO Capital | Outperform | Maintains | Sep 2, 2022 | |
| Evan Seigerman BMO Capital | Outperform | $12 | Maintains | Mar 31, 2022 |
BMO Capital | Outperform | Initiates | Nov 19, 2021 | |
Credit Suisse | Outperform | Initiates | Aug 23, 2021 | |
UBS | Buy | Initiates | Aug 23, 2021 | |
Jefferies | Buy | Initiates | Aug 23, 2021 |
When did it IPO
2021
Staff Count
42
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Market Cap
$160.8M
In 2023, CADL generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that CADL's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 29 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Recent innovations in cancer treatment are shifting focus from traditional methods to immunotherapies, which utilize the body's immune system to combat cancer.
Why It Matters - The rise of immunotherapies signals potential growth in biotech investments, as companies developing these treatments may see increased demand and market share in the evolving cancer treatment landscape.
Fri, 22 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Candel Therapeutics CEO Paul Peter Tak emphasizes the importance of patient feedback in biopharmaceutical innovation, highlighting a focus on patient-centric approaches in the industry.
Why It Matters - Candel Therapeutics' focus on patient feedback may enhance drug development success, potentially leading to better market performance and investor returns.
Thu, 14 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Candel Therapeutics (NASDAQ:CADL) aims for a "paradigm shift" in prostate cancer treatment, with phase 2b and phase 3 trial data for CAN-2409 expected in Q4 2024, potentially leading to new regulatory approvals.
Why It Matters - Candel Therapeutics' upcoming trial data for CAN-2409 could significantly impact prostate cancer treatment, potentially driving stock value and regulatory approval, influencing investor sentiment.
Sat, 09 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Candel Therapeutics (NASDAQ:CADL) presented findings on its oncolytic virus therapy, CAN-3110, at the SITC conference, highlighting advancements in cancer treatment.
Why It Matters - Candel Therapeutics' presentation on CAN-3110 highlights potential breakthroughs in cancer treatment, which could influence stock performance and investor sentiment in biotech.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Candel Therapeutics (NASDAQ:CADL) reported promising preclinical data for CAN-3110, showing antitumor activity in melanoma, potentially expanding its focus beyond glioma. Findings to be presented at SITC.
Why It Matters - Candel Therapeutics' promising preclinical data for CAN-3110 in melanoma could broaden its market potential, impacting future revenues and stock performance.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Candel Therapeutics (Nasdaq: CADL) announced preclinical results for CAN-3110 targeting melanoma. Findings will be presented at the SITC Annual Meeting from Nov 6-10, 2024.
Why It Matters - Candel Therapeutics' promising preclinical results for CAN-3110 in melanoma may attract investor interest, influencing stock performance and potential partnerships in cancer treatment advancements.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
